Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers - (Details)

v3.19.2
Revenue from Contracts with Customers - (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Disaggregation of Revenue [Line Items]        
Total revenue $ 4,449,404 $ 4,785,138 $ 9,860,847 $ 9,267,913
Prescribed dietary supplements        
Disaggregation of Revenue [Line Items]        
Total revenue 1,800,000 1,926,000 3,591,000 3,670,000
Prescription drugs        
Disaggregation of Revenue [Line Items]        
Total revenue 2,649,000 2,785,000 6,270,000 5,301,000
Sales force revenue        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0 $ 74,219 $ 0 $ 296,875
Customer Concentration Risk | Sales Revenue | Major Customer Number One        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage 38.00%   37.00%  
Customer Concentration Risk | Sales Revenue | Major Customer Number Two        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage 27.00%   30.00%  
Customer Concentration Risk | Sales Revenue | Major Customer Number Three        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage 26.00%   25.00%